Isabelle Durand‐Zaleski

Délégation Paris 5 — France

Economics, Econometrics and Finance · Social Sciences

50h-index11.9kcitations635works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(134), Healthcare Systems and Practices(51), Economic and Financial Impacts of Cancer(37), Pharmaceutical Economics and Policy(34), Health, Medicine and Society(32)

Publications632 total

Medical devices for professional use: What assessment, what funding?
Therapies·2025
SA63 Lung-Cancer Diagnostic Trajectories: A Nationwide Process-Mining Cluster Analysis of 18,569 French Patients
Value in Health·2025
Ambulatory management of primary spontaneous pneumothorax in the emergency department: EFFI-PNO protocol – a multicentre, cluster-controlled, stepped-wedge, randomised interventional study
BMJ Open·2025Open Access
SA24 Cost Variation Across Lung-Cancer Diagnostic-Pathway Clusters: A Nationwide Real-World Analysis of 18,569 French Patients
Value in Health·2025
Cost-utility of point-of-care viscoelastic hemostatic assays in the management of bleeding during cardiac surgery: A single-blinded prospective multicenter stepped wedge cluster randomized trial in French context
Anaesthesia Critical Care & Pain Medicine·2025Open Access
Remotely supervised online cognitive training to reduce cognitive difficulties following chemotherapy in patients treated for localized breast cancer: Protocol of the Cog-Stim2 multicenter randomized controlled trial
PLoS ONE·2025Open Access
Medical expenses and care pathways of patients with Pompe receiving myozyme: an observational study based on the French national healthcare database
Orphanet Journal of Rare Diseases·2025· 1 citedOpen Access
Caractéristiques des patients atteints d’un cancer du rein localement avancé ou métastatique à l’ère des combinaisons à base d’inhibiteurs de checkpoint (IO) en France et adhésion aux recommandations de l’ESMO : étude exhaustive à partir du système national des données de santé
Progrès en Urologie - FMC·2025
Evaluation of a pro-recovery training intervention (REFOCUS-RETAFORM) in specialist mental health services across France: stepped-wedge cluster randomised controlled trial protocol
BMC Psychiatry·2025Open Access
Feasibility, Effectiveness, and Cost-utility of Implementing a Reconsolidation-Based Trauma Treatment in the Aftermath of the November 13 Paris Terrorist Attacks
2025Open Access
EJS-2 Systematic genomic characterisation of cancers in 2024: worth the cost?
Annals of Oncology·2025
Policies addressing delayed discharges from hospital in France
European Journal of Public Health·2025Open Access
Outpatient Parenteral Antimicrobial Therapy in a Tertiary Hospital in France: A Description of Service Models and Costs
Antibiotics·2025Open Access
Cost-utility analysis of a web-based interactive patient education platform: evidence from a randomized clinical trial for end-stage renal disease patients
The European Journal of Health Economics·2025Open Access
Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review
The European Journal of Health Economics·2025Open Access
2618P Characteristics and real-world adherence to ESMO guidelines of patients with advanced Renal Cell Carcinoma (aRCC) in the era of immuno-oncology-based (IO) combinations in France: a national claims database study
Annals of Oncology·2025
2911TiP Cog-Stim2: Remotely supervised computerized cognitive stimulation to reduce post-chemotherapy cognitive difficulties in patients treated for localized breast cancer: An ongoing phase III trial
Annals of Oncology·2025Open Access
OPTIVENOSUS-ECO Efficiency of endovascular treatment with covered stents compared with surgical treatment in patients with sinus venosus defects: A randomized trial
Archives of cardiovascular diseases·2025
Integrating Environmental Impact in Health Technology Assessment: An Exploratory Study
PharmacoEconomics·2025· 3 citedOpen Access
Combined use of a multiplex PCR and serum procalcitonin to reduce antibiotic exposure in critically ill patients with community-acquired pneumonia: the MULTI-CAP randomized controlled trial
Intensive Care Medicine·2025· 9 cited
page 1 of 32Next →

Frequent Co-authors

Gilles Châtellier(5), Corinne Alberti(4), Michel Azizi(4), Isabelle Charreau(3), Bruno Spire(3), Catherine Capitant(3), David R. Thompson(3), Laurence Meyer(3), Christian Brun‐Buisson(3), Philippe Gabríel Steg(3), Julie Bulsei(3), Felix Mahfoud(3), Michael Böhm(3), Atul Pathak(3), Sebastian Ewen(3), Peter J. Blankestijn(3), Michel Burnier(3), Guıdo Grassı(3), Sverre E. Kjeldsen(3), Thomas F. Lüscher(3)